Coherus BioSciences to Present at Jefferies Autumn 2015 Global Healthcare Conference on November 18
November 10 2015 - 9:30AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play,
global biosimilar platform company with late-stage clinical
products, today announced that it will present at the Jefferies
Autumn 2015 Global Healthcare Conference on Wednesday, November 18
at 8:00 am GMT in London.
A webcast of the presentation will be available on the Investors
page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform
company that develops and commercializes high-quality therapeutics
for major regulated markets. Biosimilars are intended for use in
place of existing, branded biologics to treat a range of chronic
and often life-threatening diseases, with the potential to reduce
costs and expand patient access. Composed of a team of proven
industry veterans with world-class expertise in process science,
analytical characterization, protein production and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products. For additional information, please
visit www.coherus.com.
CONTACT:
Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024